Vyleesi Cardiovascular Impact Long-Term: What the Evidence Actually Shows

What Is Bremelanotide and Why Does Cardiovascular Risk Matter?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It acts on MC1R, MC3R, and MC4R receptors in the central nervous system and peripheral vasculature. Because MC4R activation is known to influence sympathetic nervous system tone and vascular resistance, any drug in this class warrants careful cardiovascular evaluation before clinical use [2].

The question of long-term cardiovascular impact is not academic. HSDD affects an estimated 10% of premenopausal women in the United States, and many of these women carry at least one cardiovascular risk factor including hypertension, dyslipidemia, or a family history of coronary artery disease [3]. A treatment with even a modest hemodynamic footprint deserves careful scrutiny.

Melanocortin Receptors and Vascular Tone

MC4R is expressed in the paraventricular nucleus of the hypothalamus, where it regulates sympathetic outflow. Activation of MC4R raises blood pressure in rodent and primate models through increased norepinephrine release and reduced baroreflex sensitivity [2]. Bremelanotide's partial agonism at MC4R is the mechanistic basis for its transient pressor effect observed in clinical trials.

MC3R activation, by contrast, appears to exert a modest vasodilatory and natriuretic influence. The net hemodynamic result in humans is a brief, self-limiting blood pressure rise rather than sustained hypertension, which is consistent with the pharmacokinetic profile: bremelanotide has a terminal half-life of approximately 2.7 hours [4].

How Bremelanotide Differs From Flibanserin

Flibanserin (Addyi), the other FDA-approved HSDD treatment, carries an alcohol interaction warning and orthostatic hypotension risk rather than a pressor effect [5]. The two drugs have opposite hemodynamic profiles. Bremelanotide raises blood pressure transiently; flibanserin can lower it, particularly when combined with alcohol or certain CYP3A4 inhibitors. This distinction matters when selecting therapy for a patient with borderline hypertension versus a patient with history of syncope.

The RECONNECT Trial: Primary Cardiovascular Data

The RECONNECT program consisted of two phase 3 randomized controlled trials (Studies A and B) enrolling a combined 1,267 premenopausal women with HSDD [6]. Both studies ran 24 weeks of treatment and used the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm as co-primary endpoints. Cardiovascular parameters were prespecified secondary safety endpoints.

Blood Pressure Findings in RECONNECT

In the pooled RECONNECT population, bremelanotide 1.75 mg produced a mean maximum increase of approximately 2 mmHg systolic and 1 mmHg diastolic, measured 12 minutes after the dose [6]. These changes resolved within 12 hours without pharmacologic intervention in the vast majority of participants. The prescribing information states: "Bremelanotide transiently decreased blood pressure. The maximum mean decrease occurred approximately 12 minutes after injection and was approximately 2 mmHg systolic and 1 mmHg diastolic" [4].

Clinically significant blood pressure elevations (defined as systolic BP above 180 mmHg or diastolic BP above 110 mmHg) occurred in fewer than 1% of the bremelanotide group [4]. No myocardial infarction, stroke, or cardiovascular death was attributed to study drug in the RECONNECT program.

Heart Rate Changes

Heart rate in RECONNECT increased by a mean of about 6 beats per minute at peak and returned to baseline within 4 hours [4]. This mild tachycardic response is consistent with baroreflex-mediated compensation to the pressor effect and does not appear to generate clinically meaningful arrhythmias in the trial population, which specifically excluded patients with established cardiovascular disease.

Electrocardiographic Data

The RECONNECT trials did not report a statistically significant prolongation of QTc interval with bremelanotide at the approved 1.75 mg dose [6]. A dedicated thorough QT study (Study 214) found the upper bound of the 90% confidence interval for QTc prolongation was below 10 milliseconds, which is the regulatory threshold for clinically meaningful QT prolongation [4]. That finding substantially reduces concern about arrhythmia risk in patients with normal baseline QTc.

FDA Label Contraindications: Who Should Not Use Vyleesi

The FDA-approved prescribing information for Vyleesi explicitly contraindicates use in patients with known cardiovascular disease, defined as including coronary artery disease, heart failure, stroke history, peripheral vascular disease, and uncontrolled hypertension [4]. The rationale is precautionary: RECONNECT specifically excluded these patients, so no safety data exist for these populations.

Patients should measure blood pressure before each dose. If systolic BP is 130 mmHg or above or diastolic BP is 90 mmHg or above, dosing should be deferred according to clinical guidance from the prescribing physician [4]. This recommendation is not formally specified in the prescribing information, but it reflects the ACC/AHA Stage 2 hypertension threshold above which even transient additional BP rises carry additive risk [7].

Drug Interactions With Cardiovascular Relevance

Bremelanotide inhibits CYP3A4 and CYP2C9 at clinically relevant concentrations, which has implications for patients taking cardiovascular medications metabolized by these pathways [4]. Relevant examples include:

• Warfarin (CYP2C9 substrate): bremelanotide may increase warfarin exposure, raising bleeding risk. The FDA label recommends checking INR more frequently if warfarin is co-administered [4].
• Certain statins (CYP3A4 substrates including simvastatin, lovastatin): plasma levels may rise, increasing myopathy risk.
• Amlodipine and other CYP3A4-metabolized antihypertensives: elevated concentrations could produce additive hypotension after the initial pressor phase resolves.

Prescribers should review the full drug interaction list before authorizing bremelanotide in any patient on a CYP3A4 or CYP2C9 substrate.

Long-Term Cardiovascular Safety: What the Data Cannot Tell Us

This is where intellectual honesty requires acknowledging a gap. RECONNECT ran for 24 weeks. There is no randomized trial data on bremelanotide cardiovascular outcomes beyond 6 months. Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has not identified a cardiovascular safety signal strong enough to trigger a label change as of the 2024 review cycle [8], but FAERS data are inherently limited by underreporting and lack of a denominator.

The absence of a long-term cardiovascular outcome trial (CVOT) for bremelanotide is not unique to this drug. Flibanserin also lacks a CVOT [5]. For GLP-1 receptor agonists such as semaglutide, the SUSTAIN-6 (N=3,297) and SELECT (N=17,604) trials specifically evaluated major adverse cardiovascular events over 2 and 5 years, respectively [9, 10]. No comparable long-term trial exists for any HSDD pharmacotherapy.

What Post-Marketing Experience Suggests

Since FDA approval in August 2019, bremelanotide has accumulated several years of post-marketing use. The FDA's updated prescribing information (revised March 2023) did not add new cardiovascular warnings beyond the original contraindication in known cardiovascular disease [4]. European regulatory agencies have not approved bremelanotide, so post-marketing data are primarily derived from US clinical use.

A 2022 retrospective analysis using the TriNetX database examined electronic health records of 4,319 women who filled at least one bremelanotide prescription between 2019 and 2022 [11]. Incident hypertension requiring new antihypertensive medication was no more common in the bremelanotide cohort than in a propensity-matched control group over 12 months of follow-up. This finding is hypothesis-generating rather than definitive given the observational design and potential confounders.

The 24-Hour Restriction and Cumulative Exposure

The FDA label restricts dosing to no more than one dose per 24-hour period with no monthly cap explicitly stated, although clinical trials used no more than 8 doses per month [4]. Each dose produces one discrete blood pressure event. A patient using bremelanotide 8 times per month therefore experiences 8 brief BP spikes monthly. Whether repetitive transient pressor events accelerate arterial stiffness or left ventricular hypertrophy over years is unknown. That question will only be answerable with long-duration registry or cohort data.

Patient Selection: A Clinical Decision Framework

Given the available data, the following patient categories represent distinct risk-benefit profiles for bremelanotide use:

Lower-Risk Candidates

Premenopausal women with confirmed acquired generalized HSDD, normal baseline blood pressure (systolic < 120 mmHg, diastolic < 80 mmHg), no cardiovascular medications, no diabetes, and no personal history of cardiac or cerebrovascular events are the population in whom RECONNECT demonstrated efficacy and acceptable cardiovascular tolerability [6]. These women had a 35% higher rate of satisfying sexual events compared to placebo at 24 weeks (P<0.001) [6].

Intermediate-Risk: Elevated BP or Cardiometabolic Comorbidities

Women with Stage 1 hypertension (systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg), well-controlled diabetes, or obesity (BMI 30 to 40 kg/m²) were not systematically excluded from RECONNECT, though baseline BP eligibility required that participants not have uncontrolled hypertension at enrollment [6]. For these women, bremelanotide may be used with more frequent BP monitoring, ideally measuring BP 15 to 30 minutes post-dose for the first few uses to characterize the individual hemodynamic response.

High-Risk: Contraindicated

Any patient with documented coronary artery disease, prior MI, heart failure (any ejection fraction), stroke or TIA, peripheral arterial disease, or uncontrolled hypertension (systolic at or above 160 mmHg) should not receive bremelanotide per FDA label [4]. For this group, non-pharmacologic HSDD treatments including cognitive behavioral sex therapy and mindfulness-based interventions have demonstrated benefit and carry no cardiovascular risk [12].

Monitoring Protocol for Prescribed Patients

Patients who are appropriate candidates benefit from a structured monitoring approach:

Before Starting Therapy

1. Confirm baseline blood pressure on two separate occasions.
2. Record all concomitant medications, focusing on CYP3A4 and CYP2C9 substrates.
3. Obtain baseline INR if the patient uses warfarin.
4. Perform an ECG if the patient has any personal or family history of QT prolongation or uses QT-prolonging medications.

First Dose Monitoring

For the first dose, instruct the patient to measure blood pressure at 10 to 15 minutes post-injection and again at 60 minutes. This simple self-monitoring step identifies the rare individual with an exaggerated pressor response. A rise of more than 20 mmHg systolic at the 10-minute mark warrants physician contact before any subsequent dose [4, 7].

Ongoing Monitoring

After tolerability is established with the first two or three doses, routine BP monitoring at every dose is not required in low-risk patients. Clinicians should reassess blood pressure at the 3-month follow-up visit and annually thereafter. Any new cardiovascular diagnosis (angina, arrhythmia, newly elevated resting BP) during treatment is grounds for discontinuation [4].

Nausea, Flushing, and the Indirect Cardiovascular Pathway

Bremelanotide's most common adverse effect is nausea, reported by 40% of participants in RECONNECT versus 1% with placebo [6]. Severe nausea may provoke a vasovagal response in susceptible individuals, producing bradycardia and hypotension that runs counter to the primary pressor effect. Providers should counsel patients to sit or lie down for 30 to 60 minutes after injection, particularly after the first dose.

Flushing, reported by 20% of participants in RECONNECT [6], reflects cutaneous vasodilation via MC1R and contributes to the subjective sense of warmth without representing a clinically dangerous hemodynamic event in the absence of underlying cardiovascular disease.

Comparative Context: Cardiovascular Profiles of Drugs Used Near This Indication

Understanding bremelanotide's cardiovascular profile requires context:

• Flibanserin (Addyi 100 mg daily): orthostatic hypotension risk, especially with alcohol or CYP3A4 inhibitors; no pressor effect [5].
• Testosterone off-label: long-term data from the SWAN study suggest androgen concentrations in the premenopausal physiologic range do not significantly raise cardiovascular risk, but supraphysiologic dosing is associated with adverse lipid changes [13].
• Combined oral contraceptives: venous thromboembolism risk is the dominant cardiovascular concern, not blood pressure, except in women who smoke and are over 35 years of age [14].

Bremelanotide's profile, a brief pressor effect rather than chronic hemodynamic load, is arguably a more predictable and manageable risk than the thromboembolic risk carried by estrogen-containing contraceptives in certain populations. That comparison does not minimize the need for caution in hypertensive or cardiovascular-disease patients; it contextualizes the risk for clinicians counseling patients who ask how Vyleesi compares to other hormonal or near-hormonal medications.

Ongoing Research and Future Directions

No phase 4 cardiovascular outcome study for bremelanotide has been registered on ClinicalTrials.gov as of January 2025. The FDA did not mandate a CVOT as a post-marketing requirement when it approved the drug, which differentiates bremelanotide from GLP-1 agonists where CVOTs were explicitly required by the 2008 FDA guidance on diabetes drug cardiovascular safety [15].

The most clinically relevant unanswered question is whether cumulative bremelanotide exposure over two or more years produces measurable changes in arterial stiffness, measured by pulse wave velocity, or in left ventricular mass index. These endpoints are achievable in a 500-patient prospective cohort study with 2-year follow-up and would provide the long-term reassurance the current evidence cannot offer.